1. COPD Management

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction

4. GOLD Executive Summary Key Revisions

5. Efficacy and Safety of SUN-101 in Moderate-To-Very-Severe COPD: GOLDEN 3 and 4

6. Long-Term Safety of SUN-101 GOLDEN-5 Study

7. Revefenacin Once-Daily LAMA for Nebulization

8. Safety Outcomes on Long-Term Use of Formoterol Fumarate Inhalation Solution

9. LAMA/LABA Dual Therapies
GOLD Executive Summary recommendation[a]
For patients with symptoms on a single long-acting bronchodilator, step-up to dual- bronchodilator therapy rather than adding on an inhaled-corticosteroid
Currently approved LAMA/LABA therapies in a single inhaler
Glycopyrrolate/formoterol fumarate
Glycopyrrolate/indacaterol
Tiotropium/olodaterol
Umeclidinium bromide/vilanterol
a. Vogelmeier CF, et al. Am J Respir Crit Care Med. 2017;195:

10. TONADO Study: Long-Term Safety of Tiotropium/Olodaterol in Elderly Patients

11. Lung Function Benefits of Glycopyrrolate/Formoterol MDI With and Without Valved Holding Chamber

12. FLIGHT Subanalysis Studies

13. GOLD Recommendations Escalating to Triple Therapy

14. Single Inhaler Triple Therapy vs Dual Therapy Subgroup Analysis of 24-Hour Serial Spirometry for the FULFIL Study

15. TRINITY Study Extrafine Fixed Triple Therapy

16. Exploring Practice Gaps in Prescribing Inhalation Delivery Devices for the Management of COPD: Results From the DMaD Survey

17. Is There a Communication Gap Between Patients and Pulmonologists in Delivery Device Selection?

18. Are Patients and Physicians on the Same Page Regarding Nebulizer Therapy?

19. Concluding Remarks

20. Abbreviations

21. Abbreviations (cont)

22. Abbreviations (cont)